Context Therapeutics | Investor Presentation Deck | 25 slides

Context Therapeutics · 2022-09
arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

25
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide uses a structured table-like layout to categorize key business and clinical updates.summarize
04
The slide uses a timeline-style visualization for clinical trial phases.plan_implementation
Open slide detailBeat · Problem (Identify pain)
05
transition
Open slide detailBeat · Problem (Identify pain)
06
The slide uses a structured table format to summarize key product attributes.present_solution
Open slide detailBeat · Solution (Provide relief)
07
The slide uses a causal chain/process flow to show how the drug combination interrupts the pathway from stimulus to cancer growth.present_solution
Open slide detailBeat · Solution (Provide relief)
08
The slide uses a table structure to map clinical strategy to market opportunity.show_traction
Open slide detailBeat · Agitate (Make it worse)
09
The slide uses a table format to link clinical trial progress with market opportunity (patient numbers) and medical need.show_traction
Open slide detailBeat · Agitate (Make it worse)
10
transition
11
The slide uses a three-column layout to show the individual strengths of the partners and the synergy of the combined therapy.argue_timing
Open slide detailLoop · Cost Of Inaction
12
The slide outlines a clinical trial protocol using a sequential phase design.present_framework
Open slide detailLoop · Cost Of Inaction
13
The slide features a person sitting on a rock overlooking a landscape, with the company logo on their jacket.transition
Open slide detailLoop · Cost Of Inaction
14
The slide provides a scientific foundation for the CLDN6xCD3 bispecific antibody program.establish_context
Open slide detailLoop · Cost Of Inaction
15
The slide highlights CLDN6 in the context of the CLDN family tree.establish_context
Open slide detailLoop · Cost Of Inaction
16
The slide uses a list-based structure to present three key pillars of the target's clinical profile.establish_context
Open slide detailLoop · Cost Of Inaction
17
The table highlights the prevalence column with an orange box.analyze_data
Open slide detailLoop · Cost Of Inaction
18
The slide illustrates the modular assembly of a bispecific antibody from two distinct components.present_solution
Open slide detailLoop · Cost Of Inaction
19
The charts show dose-response curves where the proprietary antibodies (IM301, IM302) maintain high binding to CLDN6 while showing minimal off-target binding compresent_solution
Open slide detailLoop · Cost Of Inaction
20
The slide compares the library against a benchmark (IMAB027) in terms of reactivity and cytotoxicity.present_solution
Open slide detailLoop · Cost Of Inaction
21
The slide features a person sitting on a mountain peak, which is a common visual metaphor for vision or future outlook.transition
Open slide detailLoop · Cost Of Inaction
22
other
Open slide detailLoop · Cost Of Inaction
23
The slide uses a timeline format to track progress of two distinct drug development programs.plan_implementation
Open slide detailLoop · Cost Of Inaction
24
summarize
Open slide detailLoop · Cost Of Inaction
25
front_matter